Sanara Medtech Inc. · NASDAQ:SMTI
Sanara Medtech — Investor Presentation (March 2025)
23 slides from Sanara Medtech's investor presentation, March 2025
Slide 1: Sanara MedTech Overview
Sanara MedTech Overview March 2025
Slide 2: Disclaimers
Disclaimers This presentation contains forward-looking statements that discuss expectations as to future trends, plans, events, results of operations or financial condition, or state other information relating to Sanara MedTech Inc. (the “Company,” “Sanara,” “we,” “our” or “us”). All statements othe
Slide 3: Sanara MedTech at a Glance
Sanara MedTech at a Glance Ticker (Nasdaq) SMTI A medical technology company focused on Market Cap $274.8M(1) developing and commercializing Avg. Daily Volume ~23,415(2) transformative technologies to improve • Sanara Surgical Business Segments • Tissue Health Plus clinical outcomes and reduce healt
Slide 4: The Sanara MedTech Story
The Sanara MedTech Story Continuous Innovation and Expansion Value Proposition: 2024 Sanara MedTech empowers surgeons to deliver improved patient • Tufts peptide license agreement outcomes by offering high value niche products. • $55 million debt facility to drive future growth 2022 • Signed with ma
Slide 5: Board of Directors
Board of Directors Strategic Leadership from Experienced Professionals Ron Nixon Ann Beal Salamone, M.S. Director Bob DeSutter CEO & Executive Chairman Director • Experience: Rochal Industries, EDC, • Experience: Founder, The Catalyst • Experience: Piper Sandler National Academy of Engineering, Grou
Slide 6: Sanara Surgical Segment
Sanara Surgical Segment . Sanara MedTech Evidence Based Healing
Slide 7: Sanara Surgical Segment: Demonstrated Track Record of Strong, Sustained Revenue Growth
Sanara Surgical Segment: Demonstrated Track Record of Strong, Sustained Revenue Growth Net revenues in millions $ $100.0 $90.0 $86.7 $80.0 $70.0 $65.0 $60.0 $50.0 $45.8 $40.0 $30.0 $24.1 $20.0 $15.6 $11.8 $10.0 $5.8 $0.0 2018 2019 2020 2021 2022 2023 2024 7
Slide 8: Sanara Surgical Segment: Portfolio Built to Complement Surgical Outcomes
Sanara Surgical Segment: Portfolio Built to Complement Surgical Outcomes & Reduce Post-Op Cost Empowering surgeons to deliver improved patient outcomes by offering high value niche products. Sales Overview Key Differentiators Driving Future Growth • Products sold in over 1,300 facilities in 2024, up
Slide 9: Superior Product Offering with Significant Opportunity Runway
Sanara Surgical Segment: Superior Product Offering with Significant Opportunity Runway Platform Products CellerateRX® Surgical Activated Collagen BIASURGE® Advanced Surgical Solution Surgical Cleanser Soft Tissue Surgical Powder Gel A Type I bovine Hydrolyzed collagen No rinse irrigation solution th
Slide 10: CellerateRX Surgical: Proven, Safe, and Effective
CellerateRX® Surgical Proven, Safe, and Effective Overview • CellerateRX® Surgical Powder is a medical hydrolysate of Type I bovine collagen and contains no additives • Indicated for the management of acute and chronic wounds including: • Surgical wounds • Traumatic wounds • Partial and full-thickne
Slide 11: Activated Collagen Powder Research
Activated Collagen Powder Research Study on Wound Management to Reduce Surgical Site Infections Hydrolyzed Collagen Significantly Reduces Surgical Site Infections (Nowrouzi and Awad 2023)(1) Objective: Evaluate the effect of using type 1 hydrolyzed collagen in reducing incidence of surgical site inf
Slide 12: Sanara Surgical Segment: Growth Opportunities
Sanara Surgical Segment: Growth Opportunities Existing Acute Surgical Wound Growth • The majority of CellerateRX® Surgical cases have been in the Ortho and Spine specialties. • Team is working to further penetrate the >1,200 hospitals where our products are currently sold… • …while also expanding in
Slide 13: Tissue Health Plus Segment
Tissue Health Plus Segment . Sanara MedTech Evidence Based Healing
Slide 14: Tissue Health Plus Segment: Opportunity & Overview
Tissue Health Plus Segment: Opportunity & Overview Significant Opportunity to Reduce Cost of Care in Overview of Tissue Health Plus (“THP”): Non-Surgical Wound Care: • A first of its kind value-based wound care program targeting payors • Represents ~$69B(1) of annual expenditure in U.S. hospitals, t
Slide 15: Planned Tissue Health Plus (THP) Model
Planned Tissue Health Plus (“THP”) Model Connected Payor Engaged Performant Patient Network THP Care Hub: Hands On Orchestrator INTEGRATED CARE MODEL THP SCALER PLATFORM First pilot program with a wound care provider 15 group during the second quarter of 2025
Slide 16: Q4 2024 Financial Highlights
Q4 2024 Financial Highlights
Slide 17: Q4 2024 Financial Highlights
Q4 2024 Financial Highlights (Unaudited) • Total Company • Sanara Surgical Segment • Net revenue of $26.3M (+49% year-over-year) • Segment net revenue of $26.3M in Q4 and a net revenue of $86.7M YTD • Thirteenth consecutive record net revenue quarter • Segment EBITDA(1) of $4.1M in Q4 and $9.1M YTD
Slide 18: Thank You
Thank You «. Sanara MedTech Evidence Based Healing
Slide 19: Appendix
Appendix Ye lalelge MedTech Evidence Based Healing
Slide 20: Q4 2024 Financial Summary
Q4 2024 Financial Summary (unaudited) • Revenue • For the three months ended December 31, 2024, Sanara generated net revenue of $26.3 million compared to net revenue of $17.7 million for the three months ended December 31, 2023, a 49% increase from the prior year period. • The increase in net revenu
Slide 21: Q4 2024 Financial Summary (Continued)
Q4 2024 Financial Summary (Continued) • Net Loss • Net loss for the fourth quarter of 2024 was $1.7 million compared to a net loss of $0.3 million for the fourth quarter of 2023 • Sanara Surgical segment generated net income of $0.9 million for the fourth quarter of 2024, compared to a net loss of $
Slide 22: Q4 2024 Segment Reporting
Q4 2024 Segment Reporting • Segment Reporting Overview • Break out of Tissue Health Plus and Sanara Surgical demonstrates our strategic rationale of the acute/post acute comprehensive strategy investments. Three Months Ended December 31, 2024 Three Months Ended December 31, 2023 Surgical THP Total S
Slide 23: Non-GAAP Financial Measures
Non-GAAP Financial Measures Use of Non-GAAP Financial Measures To supplement the Company’s financial information presented in accordance with generally accepted accounting principles in the United States (“GAAP”), we present certain non-GAAP financial measures in this presentation, including Adjuste